Skip to main content

Table 1 General presentation of the 10 patients with 'limited skin lupus' or toxiderma in a context of autoimmunity

From: Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey

Patient Before anti-TNF alpha treatment   During onset of symptoms
  Disease Autoantibody Clinical signs of lupus Treatment Duration of treatment (months) Clinical signs of lupus Biological signs of lupus
1 RA, erosive RF+ None ETA 36 Skin ANA+, dsDNA+
2 RA, erosive RF+ None INF 6 Skin ANA+, dsDNA+
3 RA, erosive RF+, ANA+ 1:160° None INF 18 Skin ANA+, dsDNA+
4 RA, erosive RF- None ETA 5 Skin ANA+, dsDNA+
5 RA, erosive RF+ None INF 7 Skin ANA+, dsDNA+
6 RA erosive RF+ None ETA 5 Skin ANA+, dsDNA+
7 RA, erosive RF+ None INF 11 Skin ANA+, dsDNA+
8 RA, erosive RF+ None INF 3 Skin ANA+, dsDNA+
9 RA, erosive RF+ None ETA 12 Skin ANA+, dsDNA+
10 RA, erosive RF+ None INF 13 Skin ANA+, dsDNA+
  1. ANA, antinuclear antibodies; dsDNA, double-strand DNA; ETA, etanercept; INF, infliximab; RA, rheumatoid arthritis; RF, rheumatoid factor; TNF, tumour necrosis factor; +, positive; -, negative.
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us